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The Role of Cytotoxic Therapy with Hematopoietic
Stem Cell Transplantation in the Therapy of
Myelodysplastic Syndromes135Among the primary objectives of the American
Society for Blood and Marrow Transplantation are to:
 Define commonly accepted medical and evidence-
based practice
 Develop standards of medical care for autologous
and allogeneic transplants
 Provide recommendations and guidelines for physi-
cians, patients, and third-party payers on the role of
transplantation as a therapeutic approach.
Toward this end, in 1999 the Society began spon-
soring evidence-based reviews of the scientific and
medical literature to document when blood and mar-
row transplantation is indicated in the treatment of
selected diseases.
GOALS
The goals of the evidence-based reviews are to:
 Determine which disease will be the subject of each
review, establish the focus for each review, and
develop a list of questions to be addressed
 Assemble and critically evaluate all the valid, peer-
reviewed evidence regarding the role of cytotoxic
therapy with hematopoietic stem cell transplanta-
tion related to the disease
 Provide treatment recommendations based on the
available evidence
 Identify discrepancies in study design or methodol-
ogy among published studies that may impact on the
quality of the evidence
 Identify needed areas of additional research.
GUIDELINES
The following guidelines are offered for the role
of stem cell transplantation (SCT) as therapy for
myelodysplastic syndromes (MDS), and are based
on consensus reached by an expert panel1 following
an evidence-based review of the literature.2
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Early SCT is recommended for patients with an
International Prognostic Scoring System (IPSS) score
of INT-2, considered high risk, at diagnosis who have
a suitable donor and meet the transplant center’s eligi-
bility criteria, and for selected patients at low risk
(IPSS score of INT-1) at diagnosis who have poor
prognostic features not included in the IPSS (e.g.,
older age, refractory cytopenias).
PRE-SCT INDUCTION CHEMOTHERAPY
In the absence of randomized controlled trials, in-
sufficient data are available to make a treatment rec-
ommendation for or against pre-SCT induction
chemotherapy. The decision to use pre-SCT induc-
tion therapy should be made on an individual basis.
DONOR SELECTION
1. There is no evidence of a survival advantage based
on donor relation in allogeneic SCT. In clinical
practice, matched related donor allogeneic SCT is
recommended if available. If not, unrelated donor
allogeneic SCT may provide equivalent outcomes.
2. There are sufficient data demonstrating a long-
term curative outcome for related and unrelated
allogeneic SCT.
3. Based on data and expert opinion, an HLA-
matched allogeneic donor (sibling, other family
member, unrelated individual, or cord blood)
SCT is recommended if an appropriate donor is
available. If an allogeneic donor is not available,
and complete remission is achieved with induction
therapy, then an autologous SCT can be considered
in the context of a clinical trial.
TRANSPLANTATION TECHNIQUES
1. Bone marrow transplant (BMT) versus peripheral
blood stem cell transplant (PBSCT):
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from related donors have equivalent outcomes.
 Patients with high-risk diseasemay have a survival
advantage with related donor allogeneic PBSCT.
 There is insufficient evidence to recommendBMT
versusPBSCTforunrelateddonor allogeneic SCT.
 There is no evidence of a survival advantage
based on stem cell source for autologous BMT
versus PBSCT.
2. Conditioning regimen comparisons:
 There are insufficient data to make a recommen-
dation for an optimal conditioning regimen
intensity. A range of dose intensities is currently
under investigation, and the optimal approach
likely will depend on disease and patient charac-
teristics, such as age and comorbidities.
 The are insufficient data to make a recommenda-
tion for any one high-dose conditioning regimen
over another.
AREAS OF NEEDED RESEARCH
The expert panel identified the following impor-
tant areas of needed research in MDS:
1. The benefit of using alternative donor sources
(e.g., cord blood; haploidentical family donors)
for patients without matched sibling or unrelated
donors2. The role and appropriate timing of allogeneic SCT
in combination with hypomethylating and immu-
nomodulatory treatment regimens
3. Randomized trials comparing the safety and
efficacy of various novel agents for treating MDS
4. The influence of the various MDS treatment
modalities on patient-reported quality of life
outcomes.
1Expert panel members and authors of the review are: Denise M.
Oliansky, Roswell Park Cancer Institute, Buffalo, NY; Joseph H.
Antin, Dana-Farber Cancer Institute, Boston,MA; JohnM. Bennett,
James P. Wilmot Cancer Center, University of Rochester, Roches-
ter, NY; H. Joachim Deeg, Fred Hutchinson Cancer Research Cen-
ter, Seattle, WA; Christin Engelhardt, Aplastic Anemia and MDS
International Foundation, Churchton, MD; Kathleen V. Heptin-
stall, The Myelodysplastic Syndromes Foundation, Crosswicks,
NJ; Marcos de Lima, M.D. Anderson Cancer Center, Houston,
TX; StevenD.Gore, SidneyKimmelComprehensive CancerCenter
at Johns Hopkins, Baltimore, MD; Ronald G. Potts, INTERLINK
Health Services, Hillsboro, OR; Lewis R. Silverman, Mt. Sinai
School of Medicine, New York, NY; Roy B. Jones, M.D. Anderson
Cancer Center, Houston, TX; Philip L.McCarthy, Jr., Roswell Park
Cancer Institute, Buffalo, NY; and Theresa Hahn, Roswell Park
Cancer Institute, Buffalo, NY.
2Reference: Oliansky D, Antin JH, Bennett JM, et al. The role of cy-
totoxic therapy with hematopoietic stem cell transplantation in the
therapy of myelodysplastic syndromes: an evidence-based review.
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